A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up
Objective. To evaluate the effects of once-weekly dulaglutide injection and once-daily glimepiride on glucose fluctuation in patients with type 2 diabetes mellitus (T2DM) using the Continuous Glucose Monitoring System (CGMS). Methods. A total of 23 patients with T2DM were randomly assigned into two...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2019/6423987 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545490047074304 |
|---|---|
| author | Huiqin Li Xiaohua Xu Jie Wang Xiaocen Kong Maoyuan Chen Ting Jing Zhiying Zhang Guoping Yin Xiaomei Liu Yun Hu Lei Ye Xiaofei Su Jianhua Ma |
| author_facet | Huiqin Li Xiaohua Xu Jie Wang Xiaocen Kong Maoyuan Chen Ting Jing Zhiying Zhang Guoping Yin Xiaomei Liu Yun Hu Lei Ye Xiaofei Su Jianhua Ma |
| author_sort | Huiqin Li |
| collection | DOAJ |
| description | Objective. To evaluate the effects of once-weekly dulaglutide injection and once-daily glimepiride on glucose fluctuation in patients with type 2 diabetes mellitus (T2DM) using the Continuous Glucose Monitoring System (CGMS). Methods. A total of 23 patients with T2DM were randomly assigned into two groups for 26 weeks: the dulaglutide group (n=13) and the glimepiride group (n=10). 72-hour CGMS was applied to all patients: before and after the treatment. General clinical data were collected and measured, such as fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), tumor necrosis factor-α (TNF-α), 8-iso-prostaglandin F2α (8-iso-PGF2α), and interleukin-6 (IL-6). Results. HbA1c of the dulaglutide group was reduced from 8.38±0.93% to 6.68±0.73% after the treatment (P<0.05); similarly, it was reduced from 7.91±0.98% to 6.67±0.74% (P<0.05) in the glimepiride group. The levels of serum 8-iso-PGF2α, TNF-α, and IL-6 all decreased significantly in both groups after treatment, and there was no significant difference found between the two groups (P>0.05). The Mean Blood Glucose (MBG) of the two groups declined significantly after therapy (P<0.05). However, the Standard Deviation of Blood Glucose (SDBG) decreased significantly only in the dulaglutide group (from 2.57±0.74 mmol/L to 1.98±0.74 mmol/L, P<0.05). There were no significant changes of Mean Amplitude of Glycemic Excursion (MAGE) and Absolute Means of Daily Difference (MODD) after treatment in both groups. Furthermore, no statistically significant difference was found between the two groups in MBG, SDBG, MAGE, and MODD (P>0.05). The percentage time (PT) (>10 mmol/L and 3.9-10 mmol/L) of the two groups was significantly changed after the treatment (P<0.05). However, this was not seen in the PT<3.9 mmol/L after the treatment (P>0.05). Conclusion. Once-weekly dulaglutide injection has the same effectiveness as daily glimepiride on lowering blood glucose and decreasing oxidation stress and inflammation and is more effective in controlling glucose fluctuation as compared with glimepiride. This trial is registered with ClinicalTrials.gov NCT01644500. |
| format | Article |
| id | doaj-art-25a30486503d4d00961369134969eb75 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-25a30486503d4d00961369134969eb752025-02-03T07:25:35ZengWileyJournal of Diabetes Research2314-67452314-67532019-01-01201910.1155/2019/64239876423987A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-UpHuiqin Li0Xiaohua Xu1Jie Wang2Xiaocen Kong3Maoyuan Chen4Ting Jing5Zhiying Zhang6Guoping Yin7Xiaomei Liu8Yun Hu9Lei Ye10Xiaofei Su11Jianhua Ma12Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaNational Heart Research Institute Singapore, National Heart Centre Singapore, SingaporeDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, ChinaObjective. To evaluate the effects of once-weekly dulaglutide injection and once-daily glimepiride on glucose fluctuation in patients with type 2 diabetes mellitus (T2DM) using the Continuous Glucose Monitoring System (CGMS). Methods. A total of 23 patients with T2DM were randomly assigned into two groups for 26 weeks: the dulaglutide group (n=13) and the glimepiride group (n=10). 72-hour CGMS was applied to all patients: before and after the treatment. General clinical data were collected and measured, such as fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), tumor necrosis factor-α (TNF-α), 8-iso-prostaglandin F2α (8-iso-PGF2α), and interleukin-6 (IL-6). Results. HbA1c of the dulaglutide group was reduced from 8.38±0.93% to 6.68±0.73% after the treatment (P<0.05); similarly, it was reduced from 7.91±0.98% to 6.67±0.74% (P<0.05) in the glimepiride group. The levels of serum 8-iso-PGF2α, TNF-α, and IL-6 all decreased significantly in both groups after treatment, and there was no significant difference found between the two groups (P>0.05). The Mean Blood Glucose (MBG) of the two groups declined significantly after therapy (P<0.05). However, the Standard Deviation of Blood Glucose (SDBG) decreased significantly only in the dulaglutide group (from 2.57±0.74 mmol/L to 1.98±0.74 mmol/L, P<0.05). There were no significant changes of Mean Amplitude of Glycemic Excursion (MAGE) and Absolute Means of Daily Difference (MODD) after treatment in both groups. Furthermore, no statistically significant difference was found between the two groups in MBG, SDBG, MAGE, and MODD (P>0.05). The percentage time (PT) (>10 mmol/L and 3.9-10 mmol/L) of the two groups was significantly changed after the treatment (P<0.05). However, this was not seen in the PT<3.9 mmol/L after the treatment (P>0.05). Conclusion. Once-weekly dulaglutide injection has the same effectiveness as daily glimepiride on lowering blood glucose and decreasing oxidation stress and inflammation and is more effective in controlling glucose fluctuation as compared with glimepiride. This trial is registered with ClinicalTrials.gov NCT01644500.http://dx.doi.org/10.1155/2019/6423987 |
| spellingShingle | Huiqin Li Xiaohua Xu Jie Wang Xiaocen Kong Maoyuan Chen Ting Jing Zhiying Zhang Guoping Yin Xiaomei Liu Yun Hu Lei Ye Xiaofei Su Jianhua Ma A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up Journal of Diabetes Research |
| title | A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up |
| title_full | A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up |
| title_fullStr | A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up |
| title_full_unstemmed | A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up |
| title_short | A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up |
| title_sort | randomized study to compare the effects of once weekly dulaglutide injection and once daily glimepiride on glucose fluctuation of type 2 diabetes mellitus patients a 26 week follow up |
| url | http://dx.doi.org/10.1155/2019/6423987 |
| work_keys_str_mv | AT huiqinli arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT xiaohuaxu arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT jiewang arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT xiaocenkong arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT maoyuanchen arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT tingjing arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT zhiyingzhang arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT guopingyin arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT xiaomeiliu arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT yunhu arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT leiye arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT xiaofeisu arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT jianhuama arandomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT huiqinli randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT xiaohuaxu randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT jiewang randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT xiaocenkong randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT maoyuanchen randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT tingjing randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT zhiyingzhang randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT guopingyin randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT xiaomeiliu randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT yunhu randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT leiye randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT xiaofeisu randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup AT jianhuama randomizedstudytocomparetheeffectsofonceweeklydulaglutideinjectionandoncedailyglimepirideonglucosefluctuationoftype2diabetesmellituspatientsa26weekfollowup |